Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Stemline Therapeutics Inc.
DescriptionHuman mAb against CD123
Molecular Target Interleukin-3 (IL-3) receptor alpha (CD123)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationLeukemia
Indication DetailsTreat leukemia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today